Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.24064PMID 19152438PMCID PMC2931827
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug Insight: role of the androgen receptor in the development and progression of prostate cancer

  2007cited by this paper
• Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

  2007cited by this paper
• Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

  2007cited by this paper
• Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

  2006cited by this paper
• Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

  2006influential reference
• Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy

  2006cited by this paper
• Development of an integrated prostate cancer research information system.

  2006cited by this paper
• Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

  2005cited by this paper
• Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

  2005cited by this paper
• Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.

  2005cited by this paper
• Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

  2004cited by this paper
• American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.

  2004cited by this paper
• Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer

  2000cited by this paper
• Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

  1998cited by this paper
• PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.

  1997cited by this paper

• Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

  2026influential citation
• PSA Zero Radiographic Disease Progression on PSMA PET/CT

  2026cites this paper
• PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?

  2025cites this paper
• The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis.

  2025cites this paper
• PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.

  2025cites this paper
• PSA im Extrembereich – Ausdruck einer infausten Prognose?

  2025cites this paper
• Akkermansia muciniphila Metabolite Inosine Inhibits Castration Resistance in Prostate Cancer

  2024cites this paper
• PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide

  2024cites this paper
• Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer

  2024cites this paper
• Independent association between prostate-specific antigen nadir and PSA progression-free survival in first-line abiraterone acetate treatment in castration-resistant prostate cancer patients: a pilot study

  2024cites this paper
• Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment.

  2023cites this paper
• Dynamic changes in PSA levels predict prognostic outcomes in prostate cancer patients undergoing androgen -deprivation therapy: A multicenter retrospective analysis

  2023cites this paper
• Prognostic significance of nadir PSA value and time to nadir PSA in patients with metastatic castration-naive prostate cancer receiving first-line hormonotherapy

  2023cites this paper
• Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study.

  2023cites this paper
• Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.

  2023cites this paper
• Low PSA radiographic disease progression on C11‐choline PET

  2023cites this paper
• Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

  2023cites this paper
• Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer

  2022cites this paper
• The slope associated with nadir prostate‐specific antigen is prognostically significant in men with hormone‐sensitive prostate cancer after primary androgen deprivation therapy

  2022cites this paper
• Effectiveness of GnRH Antagonists and Agonists in Patients with Hormone-Sensitive Prostate Cancer: A Retrospective Study

  2022cites this paper
• Flare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients

  2022cites this paper
• Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer

  2022cites this paper
• Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.

  2022cites this paper
• Prostate-Specific Antigen and Time to PSA Nadir as Prognostic Significance in Castration-Resistant Prostate Cancer

  2022cites this paper
• Affordable and underutilized: the paradox of surgical castration

  2021cites this paper
• High Serum Alkaline Phosphatase Flare after First-Line Androgen Deprivation Therapy Predicts Poor Prognosis in Metastatic Prostate Cancer Patients Treated with Second-Generation Androgen Receptor Targeted Therapy

  2021cites this paper
• Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy

  2021cites this paper
• Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer

  2021cites this paper
• Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer

  2021cites this paper
• PSA Nadir and Time to PSA Nadir Following Androgen Deprivation Therapy are the Predictors for Castration-Resistant Prostate Cancer in Patients with Metastatic Prostate Cancer

  2021cites this paper
• Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy

  2020cites this paper
• Choice of treatment options for metastatic hormone-sensitive prostate cancer

  2020cites this paper
• EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer

  2020cites this paper
• Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone

  2020cites this paper
• Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer.

  2020cites this paper
• Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry.

  2020cites this paper
• Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan

  2020cites this paper
• Metastatic Prostate Cancer under Androgen Deprivation Therapy: Factors Influencing Castration Resistance

  2020cites this paper
• Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review

  2020cites this paper
• Weill Cornell Medicine.

  2020cites this paper
• Доцетаксел и бисфосфонаты при гормоночувствительном раке предстательной железы

  2020cites this paper
• Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry

  2020cites this paper
• RRU_A_204507 137..142

  2019cites this paper
• Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain.

  2019cites this paper
• Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer

  2019cites this paper
• Impact of tumor cytoreduction in metastatic prostate cancer

  2019cites this paper
• Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer

  2019cites this paper
• Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer

  2019cites this paper
• Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA)

  2019cites this paper
• Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients

  2019cites this paper
• PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.

  2019cites this paper
• Efficacy and outcome of holmium laser enucleation of prostate in patients with urinary retention due to advanced prostate cancer

  2019cites this paper
• Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATIT

  2019cites this paper
• Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain

  2019cites this paper
• Prostate-Specific Antigen Levels of Prostate Cancer Patients Three Months Following LHRH Agonist Therapy

  2019cites this paper
• Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer

  2019cites this paper
• [CLINICAL STUDY OF THE PROSTATE CANCERS WITH A SERUM PROSTATE SPECIFIC ANTIGEN LEVEL OF MORE THAN 100 ng/ml AT THE FIRST DIAGNOSIS].

  2019cites this paper
• Prostate Cancer

  2019cites this paper
• Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy.

  2019cites this paper
• Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy.

  2019cites this paper
• Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer

  2018cites this paper
• Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy

  2018cites this paper
• Prostate specific antigen ( PSA ) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy :

  2018cites this paper
• Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis

  2018cites this paper
• Survival analysis and development of a prognostic nomogram for bone‐metastatic prostate cancer patients: A single‐center experience in Indonesia

  2018cites this paper
• The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients

  2018influential citation
• Prostate-specific antigen decline pattern in advanced prostate cancer receiving androgen deprivation therapy and relationship with prostate-specific antigen progression

  2017influential citation
• Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.

  2017cites this paper
• Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

  2017cites this paper
• Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer

  2017cites this paper
• Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate‐specific antigen nadir level

  2017cites this paper
• Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review

  2017cites this paper
• First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.

  2017cites this paper
• PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China

  2017cites this paper
• Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer

  2017cites this paper
• Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer

  2017cites this paper
• Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy

  2016cites this paper
• The Role of Prostate‐Specific Antigen (PSA) and PSA Kinetics in the Management of Advanced Prostate Cancer

  2016cites this paper
• Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer

  2016cites this paper
• Factores asociados con la respuesta a la terapia de privación androgénica en pacientes con cáncer de próstata y metástasis óseas en una institución

  2016cites this paper
• Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer

  2016cites this paper
• QUINAZOLINE + BASED ! ALPHA 1 + ADRENOCEPTOR ! ANTAGONISTS ! AND ! PROSTATE ! CANCER !

  2016cites this paper
• Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy

  2016cites this paper
• Association of microRNA‐21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy

  2016cites this paper
• Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.

  2016cites this paper
• Cancers de la prostate de score de Gleason supérieur ou égal à 8: Evaluation de la survie des patients

  2016cites this paper
• The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.

  2015influential citation
• Discovery of Prostate Specific Antigen Pattern to Predict Castration Resistant Prostate Cancer of Androgen Deprivation Therapy

  2015cites this paper
• Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels

  2015cites this paper
• Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy

  2015cites this paper
• Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist

  2015cites this paper
• Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.

  2015influential citation
• Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy

  2015cites this paper
• The Role of Single Nucleotide Polymorphisms in Predicting Prostate Cancer Risk and Therapeutic Decision Making

  2014cites this paper
• Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)

  2014cites this paper
• The Utility of Combination of Prostate Specific Antigen ( Psa ) Nadir Level and Time to Psa Nadir Following Androgen Deprivation Therapy as a Reliable Prognostic Factor in Advanced Prostate Cancer

  2014influential citation
• Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy

  2014influential citation
• Nicotinamide N-methyltransferase is overexpressed in prostate cancer and correlates with prolonged progression-free and overall survival times

  2014cites this paper
• Predictive Clinical Indicators of Biochemical Progression in Advanced Prostate Cancer Patients Receiving Leuplin Depot as Androgen Deprivation Therapy

  2014cites this paper
• Prognostic Impact of Time to Undetectable Prostate-Specific Antigen in Patients with Positive Surgical Margins Following Radical Prostatectomy

  2014cites this paper